Sulforaphane as a treatment for mild to moderate depression in post percutaneous coronary intervention patients: A randomized double blind and placebo controlled clinical trial
Red color represents old content. It may be empty showing addition in the new version.
Green color represents new content. It may be empty showing deletion in the new version.
Inline
Side by side
Added new contents,
deleted old contents,contents that are not changed.
New table contents
New table contents
Old table contents
Old table contents
Unchanged contents
Unchanged contents
Added new contents, contents that are not changed.
Deleted old contents, contents that are not changed.
Old table contents
Old table contents
Unchanged contents
Unchanged contents
New table contents
New table contents
Unchanged contents
Unchanged contents
General information
18
40
1840
50
65
5065
empty
We have to find older patients
We have to find older patients
empty
ما مجبوریم ماکزیم سن را تا 65 سال افزایش دهیم تا به حجم نمونه برسیم
ما مجبوریم ماکزیم سن را تا 65 سال افزایش دهیم تا به حجم نمونه برسیم
Based on DSM-5 diagnostic criteria, have minor depression disorder
Based on Hamilton depression scale, get the score of 14 to 17
Age between 18 to 50 years
History of percutaneous coronary intervention
Based on DSM-5 diagnostic criteria, have minor depression disorder
Based on Hamilton depression scale, get the score of 14 to 17
Age between 40 to 65 years
History of percutaneous coronary intervention
Based on DSM-5 diagnostic criteria, have minor depression disorder Based on Hamilton depression scale, get the score of 14 to 17 Age between 1840 to 5065 years History of percutaneous coronary intervention
بر اساس معیار تشخیصی DSM-5 اختلال افسردگی مینور داشته باشند
بیماران بر اساس Hamilton depression scale نمره 14 تا 17 کسب کرده باشند
سن بین 18 تا 50 سال
سابقه آنژیوپلاستی عروق قلبی
بر اساس معیار تشخیصی DSM-5 اختلال افسردگی مینور داشته باشند
بیماران بر اساس Hamilton depression scale نمره 14 تا 17 کسب کرده باشند
سن بین 40 تا 65 سال
سابقه آنژیوپلاستی عروق قلبی
بر اساس معیار تشخیصی DSM-5 اختلال افسردگی مینور داشته باشند بیماران بر اساس Hamilton depression scale نمره 14 تا 17 کسب کرده باشند سن بین 1840 تا 5065 سال سابقه آنژیوپلاستی عروق قلبی
Protocol summary
Study aim
Studying the effect of Sulforaphane on the treatment of mild to moderate depression in post percutaneous coronary intervention patients
Design
Randomized double blind and placebo-controlled clinical trial
Settings and conduct
The study will be performed on patients with heart disease who underwent percutaneous coronary intervention, and with mild to moderate depression attending Roozbeh Hospital
Participants/Inclusion and exclusion criteria
Inclusion criteria: based on DSM-5 diagnostic criteria, have minor depression disorder; based on Hamilton depression scale, get the score of 14 to 17; age between 18 to 50 years old; history of percutaneous coronary intervention. Exclusion criteria: pregnant or lactating women; presence of other psychiatric disorders; be psychotic; history of Electroconvulsive therapy; two months prior to the trial; using psychotropic drug; drug addiction; presence of thyroid disease.
Intervention groups
Patients with mild to moderate depression (based on DSM-5 diagnostic criteria) are included in the study and divided into two control (25 participants) and intervention (25 participants) groups. Patients in the intervention group receive Sulforaphane tablet for 6 weeks, and patients in the control group receive placebo for 6 weeks. Patients are assessed at weeks 0, 2, 4, and 6 by Hamilton depression scale. Side effects of the drug are assessed at weeks 1, 2, 4 and 6.
Main outcome variables
Severity of depression
General information
Reason for update
We have to find older patients
Acronym
IRCT registration information
IRCT registration number:IRCT20090117001556N128
Registration date:2020-05-19, 1399/02/30
Registration timing:prospective
Last update:2021-01-02, 1399/10/13
Update count:1
Registration date
2020-05-19, 1399/02/30
Registrant information
Name
Shahin Akhondzadeh
Name of organization / entity
Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 21 5541 2222
Email address
s.akhond@sina.tums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2020-06-21, 1399/04/01
Expected recruitment end date
2022-06-22, 1401/04/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Sulforaphane as a treatment for mild to moderate depression in post percutaneous coronary intervention patients: A randomized double blind and placebo controlled clinical trial
Public title
The effect of Sulforaphane on the treatment of mild to moderate depression in post percutaneous coronary intervention patients
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Based on DSM-5 diagnostic criteria, have minor depression disorder
Based on Hamilton depression scale, get the score of 14 to 17
Age between 40 to 65 years
History of percutaneous coronary intervention
Exclusion criteria:
Pregnant or lactating women
Presence of other psychiatric disorders
Be psychotic
History of Electroconvulsive therapy, two months prior to the trial
Using psychotropic drug
Drug addiction
Presence of Thyroid disease
Age
From 40 years old to 65 years old
Gender
Both
Phase
2-3
Groups that have been masked
Participant
Care provider
Outcome assessor
Sample size
Target sample size:
50
Randomization (investigator's opinion)
Randomized
Randomization description
Permuted block randomization: using A and B blocks with n=4; AABB, ABAB, ABBA, BABA, BAAB, BBAA. We randomly use the blocks to achieve total sample size. ("A" and "B" are the study groups)
Blinding (investigator's opinion)
Double blinded
Blinding description
The participants, care providers and outcome assessors will be blind regarding grouping. All the participants believe that they are taking the main medication (the participants who are taking placebo are not aware of it). Care providers and outcome assessors do not know which participants have received the main medication and which participants have received placebo. Thus, there is no orientation in their work process.
Placebo
Used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics Committee of Tehran University of Medical Sciences
Street address
Tehran University of Medical Sciences, Qhods St., Keshavarz Blvd.
City
Tehran
Province
Tehran
Postal code
1417653761
Approval date
2019-12-22, 1398/10/01
Ethics committee reference number
IR.TUMS.VCR.REC.1398.1004
Health conditions studied
1
Description of health condition studied
Depression
ICD-10 code
F32.1
ICD-10 code description
Major depressive disorder, single episode, moderate
Primary outcomes
1
Description
Severity of depression
Timepoint
Baseline and weeks 2, 4, and 6
Method of measurement
By Hamilton depression scale
Secondary outcomes
empty
Intervention groups
1
Description
Intervention group: Sulforaphane tablet (ACECR, Tehran), 30 mg per day for 6 weeks
Category
Treatment - Drugs
2
Description
Control group: Placebo, once a day for 6 weeks
Category
Placebo
Recruitment centers
1
Recruitment center
Name of recruitment center
Roozbeh hospital
Full name of responsible person
Prof. Mohammad Reza Mohammadi
Street address
Roozbeh Hospital, South Kargar Street
City
Tehran
Province
Tehran
Postal code
1333715914
Phone
+98 21 5541 2222
Email
mohammadimr@tums.ac.ir
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Dr. Mohammad Ali Sahraian
Street address
Tehran University of Medical Sciences, Qhods St., Keshavarz Blvd.
City
Tehran
Province
Tehran
Postal code
1417653761
Phone
+98 21 8898 7381
Email
msahrai@tums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
No
Title of funding source
Tehran University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic
Person responsible for general inquiries
Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Shahin Akhondzadeh
Position
Professor of clinical psychopharmacology
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Roozbeh Hospital, South Kargar Street, Tehran
City
Tehran
Province
Tehran
Postal code
1333715914
Phone
+98 21 5541 2222
Email
s.akhond@sina.tums.ac.ir
Person responsible for scientific inquiries
Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Prof. Shahin Akhondzadeh
Position
Professor of clinical psychopharmacology
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Roozbeh Hospital, South Kargar Street, Tehran
City
Tehran
Province
Tehran
Postal code
1333715914
Phone
+98 21 5541 2222
Email
s.akhond@sina.tums.ac.ir
Person responsible for updating data
Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Shahin Akhondzadeh
Position
Professor of clinical psychopharmacology
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Roozbeh Hospital, South Kargar Street
City
Tehran
Province
Tehran
Postal code
1333715914
Phone
+98 21 5541 2222
Fax
+98 21 5541 9113
Email
s.akhond@sina.tums.ac.ir
Sharing plan
Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
No - There is not a plan to make this available
Title and more details about the data/document
The data will be distributed through final report
When the data will become available and for how long
5 years from 2021 to 2026
To whom data/document is available
academic researchers
Under which criteria data/document could be used
users should cite the resource of data
From where data/document is obtainable
Prof Shahin Akhondzadeh
What processes are involved for a request to access data/document